Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The renoprotective effect of once-weekly GLP-1 receptor agonist dulaglutide on progression of nephropathy in Japanese patients with type 2 diabetes and moderate to severe chronic kidney disease (JDDM67).
Tsuchida KI, Taneda S, Yokota I, Okada K, Kurihara Y, Yokoyama H, Iwamoto M, Yamazaki K, Ishigaki Y, Manda N, Maegawa H; Japan Diabetes Clinical Data Management Study Group (JDDM study group). Tsuchida KI, et al. J Diabetes Investig. 2022 Nov;13(11):1834-1841. doi: 10.1111/jdi.13877. Epub 2022 Jul 5. J Diabetes Investig. 2022. PMID: 35735780 Free PMC article.
Improved time in range and postprandial hyperglycemia with canagliflozin in combination with teneligliptin: Secondary analyses of the CALMER study.
Cho KY, Nomoto H, Nakamura A, Kawata S, Sugawara H, Takeuchi J, Nagai S, Omori K, Tsuchida K, Miya A, Shigesawa I, Tsuchida K, Yanagiya S, Kameda H, Yokoyama H, Taneda S, Kurihara Y, Aoki S, Nishimoto N, Atsumi T, Miyoshi H. Cho KY, et al. J Diabetes Investig. 2021 Aug;12(8):1417-1424. doi: 10.1111/jdi.13498. Epub 2021 Feb 5. J Diabetes Investig. 2021. PMID: 33421309 Free PMC article. Clinical Trial.
Trends in glycemic control in patients with insulin therapy compared with non-insulin or no drugs in type 2 diabetes in Japan: a long-term view of real-world treatment between 2002 and 2018 (JDDM 66).
Yokoyama H, Araki SI, Yamazaki K, Kawai K, Shirabe SI, Oishi M, Kanatsuka A, Yagi N, Kabata D, Shintani A, Maegawa H; JDDM study group. Yokoyama H, et al. BMJ Open Diabetes Res Care. 2022 May;10(3):e002727. doi: 10.1136/bmjdrc-2021-002727. BMJ Open Diabetes Res Care. 2022. PMID: 35504696 Free PMC article.
A Comparison of the Effects of the GLP-1 Analogue Liraglutide and Insulin Glargine on Endothelial Function and Metabolic Parameters: A Randomized, Controlled Trial Sapporo Athero-Incretin Study 2 (SAIS2).
Nomoto H, Miyoshi H, Furumoto T, Oba K, Tsutsui H, Miyoshi A, Kondo T, Tsuchida K, Atsumi T, Manda N, Kurihara Y, Aoki S; SAIS Study Group. Nomoto H, et al. PLoS One. 2015 Aug 18;10(8):e0135854. doi: 10.1371/journal.pone.0135854. eCollection 2015. PLoS One. 2015. PMID: 26284918 Free PMC article. Clinical Trial.
The effects of vildagliptin compared with metformin on vascular endothelial function and metabolic parameters: a randomized, controlled trial (Sapporo Athero-Incretin Study 3).
Kitao N, Miyoshi H, Furumoto T, Ono K, Nomoto H, Miya A, Yamamoto C, Inoue A, Tsuchida K, Manda N, Kurihara Y, Aoki S, Nakamura A, Atsumi T; SAIS Study Group. Kitao N, et al. Cardiovasc Diabetol. 2017 Oct 10;16(1):125. doi: 10.1186/s12933-017-0607-6. Cardiovasc Diabetol. 2017. PMID: 29017497 Free PMC article. Clinical Trial.
[Acute renal failure probably induced by Tamm-Horsfall protein].
Tsuchida K, Ozawa T, Iwamoto M, Akizuki M, Tsuchihashi K, Masuda H, Nakamura N, Nagashima Y. Tsuchida K, et al. Nihon Naika Gakkai Zasshi. 2000 Jun 10;89(6):1191-3. Nihon Naika Gakkai Zasshi. 2000. PMID: 10892197 Japanese. No abstract available.
Inclusion bodies of aggregated hemosiderins in liver macrophages.
Hayashi H, Tatsumi Y, Wakusawa S, Shigemasa R, Koide R, Tsuchida KI, Morotomi N, Yamashita T, Kumagai K, Ono Y, Hayashi K, Ishigami M, Goto H, Kato A, Kato K. Hayashi H, et al. Among authors: tsuchida ki. Med Mol Morphol. 2017 Dec;50(4):205-210. doi: 10.1007/s00795-017-0163-x. Epub 2017 Jun 19. Med Mol Morphol. 2017. PMID: 28631037
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
16 results